http://rdf.ncbi.nlm.nih.gov/pubchem/patent/CN-106967740-B
Outgoing Links
| Predicate | Object |
|---|---|
| classificationCPCAdditional | http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07K2319-35 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A23V2002-00 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K38-00 |
| classificationCPCInventive | http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A23L3-3535 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07K14-37 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C12N15-70 |
| classificationIPCInventive | http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C12N15-70 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A23L33-195 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K47-64 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K38-16 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A23L3-3535 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A23K20-147 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C07K19-00 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61P31-04 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C12N15-62 |
| filingDate | 2017-02-17-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| grantDate | 2020-11-13-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| publicationDate | 2020-11-13-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| publicationNumber | CN-106967740-B |
| titleOfInvention | Escherichia coli fusion expression plectasin, preparation method and application thereof |
| abstract | The invention discloses a fusion expression plectasin, a preparation method and application thereof, wherein the amino acid sequence of the recombinant plectasin is SEQ ID NO. 1; the nucleotide sequence designed according to the preferred codon of the escherichia coli is SEQ ID NO. 2. The invention constructs escherichia coli BL21(DE3) host bacteria capable of expressing plectasin-thioredoxin fusion protein by using prokaryotic expression vectors. The strain is subjected to amplification culture, induced expression is carried out through isopropyl-beta-D-thiogalactoside, thalli are obtained through centrifugation, supernatant is obtained through centrifugation after thalli are cracked, myceliophycin fusion protein is obtained through affinity chromatography purification, and the growth of gram-positive staphylococcus aureus, streptococcus pneumoniae and the like can be remarkably inhibited without removing thioredoxin through enzyme digestion. The invention can have obvious bacteriostatic action without enzyme digestion to remove the fusion protein, thereby greatly reducing the production cost. |
| priorityDate | 2017-02-17-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| type | http://data.epo.org/linked-data/def/patent/Publication |
Incoming Links
Total number of triples: 161.